Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



U.K. Trade Balance (Oct)A:--
F: --
P: --
France HICP Final MoM (Nov)A:--
F: --
P: --
China, Mainland Outstanding Loans Growth YoY (Nov)A:--
F: --
P: --
China, Mainland M2 Money Supply YoY (Nov)A:--
F: --
P: --
China, Mainland M0 Money Supply YoY (Nov)A:--
F: --
P: --
China, Mainland M1 Money Supply YoY (Nov)A:--
F: --
P: --
India CPI YoY (Nov)A:--
F: --
P: --
India Deposit Gowth YoYA:--
F: --
P: --
Brazil Services Growth YoY (Oct)A:--
F: --
P: --
Mexico Industrial Output YoY (Oct)A:--
F: --
P: --
Russia Trade Balance (Oct)A:--
F: --
P: --
Philadelphia Fed President Henry Paulson delivers a speech
Canada Building Permits MoM (SA) (Oct)A:--
F: --
P: --
Canada Wholesale Sales YoY (Oct)A:--
F: --
P: --
Canada Wholesale Inventory MoM (Oct)A:--
F: --
P: --
Canada Wholesale Inventory YoY (Oct)A:--
F: --
P: --
Canada Wholesale Sales MoM (SA) (Oct)A:--
F: --
P: --
Germany Current Account (Not SA) (Oct)A:--
F: --
P: --
U.S. Weekly Total Rig CountA:--
F: --
P: --
U.S. Weekly Total Oil Rig CountA:--
F: --
P: --
Japan Tankan Small Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Large Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Small Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large-Enterprise Capital Expenditure YoY (Q4)A:--
F: --
P: --
U.K. Rightmove House Price Index YoY (Dec)A:--
F: --
P: --
China, Mainland Industrial Output YoY (YTD) (Nov)A:--
F: --
P: --
China, Mainland Urban Area Unemployment Rate (Nov)A:--
F: --
P: --
Saudi Arabia CPI YoY (Nov)--
F: --
P: --
Euro Zone Industrial Output YoY (Oct)--
F: --
P: --
Euro Zone Industrial Output MoM (Oct)--
F: --
P: --
Canada Existing Home Sales MoM (Nov)--
F: --
P: --
Euro Zone Total Reserve Assets (Nov)--
F: --
P: --
U.K. Inflation Rate Expectations--
F: --
P: --
Canada National Economic Confidence Index--
F: --
P: --
Canada New Housing Starts (Nov)--
F: --
P: --
U.S. NY Fed Manufacturing Employment Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing Index (Dec)--
F: --
P: --
Canada Core CPI YoY (Nov)--
F: --
P: --
Canada Manufacturing Unfilled Orders MoM (Oct)--
F: --
P: --
U.S. NY Fed Manufacturing Prices Received Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing New Orders Index (Dec)--
F: --
P: --
Canada Manufacturing New Orders MoM (Oct)--
F: --
P: --
Canada Core CPI MoM (Nov)--
F: --
P: --
Canada Trimmed CPI YoY (SA) (Nov)--
F: --
P: --
Canada Manufacturing Inventory MoM (Oct)--
F: --
P: --
Canada CPI YoY (Nov)--
F: --
P: --
Canada CPI MoM (Nov)--
F: --
P: --
Canada CPI YoY (SA) (Nov)--
F: --
P: --
Canada Core CPI MoM (SA) (Nov)--
F: --
P: --
Canada CPI MoM (SA) (Nov)--
F: --
P: --
Federal Reserve Board Governor Milan delivered a speech
U.S. NAHB Housing Market Index (Dec)--
F: --
P: --
Australia Composite PMI Prelim (Dec)--
F: --
P: --
Australia Services PMI Prelim (Dec)--
F: --
P: --
Australia Manufacturing PMI Prelim (Dec)--
F: --
P: --
Japan Manufacturing PMI Prelim (SA) (Dec)--
F: --
P: --
U.K. Unemployment Rate (Nov)--
F: --
P: --
U.K. 3-Month ILO Unemployment Rate (Oct)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
It’s time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning!
Moving stocks this morning are clinical trial updates, earnings reports and more.
Let’s get into that news below!
Biggest Pre-Market Stock Movers: 10 Top Gainers
10 Top Losers
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More from InvestorPlace
ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET.
Conference Call and Webcast PresentationDate and Time: Wednesday, July 31, 2024 at 8:00 a.m. ETToll Free: 1-877-407-0792International: 1-201-689-8263Conference ID: 13748183
Webcast Presentation: Click here
A replay of the webcast, when available, will be posted to Bionomics’ website Events page under the Investors section.
FOR FURTHER INFORMATION PLEASE CONTACT:
| GeneralRajeev Chandra Company SecretaryCoSec@bionomics.com.au | Investor RelationsKevin Gardnerkgardner@lifesciadvisors.com | Investor RelationsChris Calabreseccalabrese@lifesciadvisors.com |
About Bionomics LimitedBionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au
https://www.globenewswire.com/newsroom/ti?nf=OTE5NTIyMiM2Mzk3MjI4IzIyNDQxNzE=https://ml.globenewswire.com/media/YWZkMDZlNzMtNzgzZS00NTFiLTkxMGMtNzg5ODFmODdlY2UyLTEyNTU3MjQ=/tiny/Bionomics-Ltd.pngPre-market stock movers are a hot topic on Friday as we check out all of the latest stories affecting shares on the last day of trading this week!
Moving stocks this morning are a Maui fire settlement report, a reverse stock split notice, earnings reports and more.
Let’s get into that news below!
Biggest Pre-Market Stock Movers: 10 Top Gainers
10 Top Losers
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More from InvestorPlace
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!
Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.
Let’s get into that news below!
Biggest Pre-Market Stock Movers: 10 Top Gainers
10 Top Losers
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More from InvestorPlace
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up